CI
PCVX icon

Cordant Inc’s Vaxcyte PCVX Stock Holding History

Cordant Inc’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140 Buy
+2
New +$109 ﹤0.01% 313

Other funds holding PCVX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AWM
Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
CAL
Capital Advisors Ltd Shaker Heights, Ohio $991M AUM 19.82% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
AFC
Ares Financial Consulting Calabasas, California $139M AUM

Cordant Inc's PCVX Position: Q2 2026 in Review

Cordant Inc opened a new position in Vaxcyte (PCVX) in Q2 2026: 2 shares worth $140. The stake represents ﹤0.01% of the portfolio and ranks #313 among its holdings.

16 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Cordant Inc held 2 shares of Vaxcyte worth $140 as of Q2 2026.
  • Vaxcyte was a new Cordant Inc position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Cordant Inc's portfolio in Q2 2026, its #313 holding.
  • 16 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Cordant Inc's 13F filing for Q2 2026, filed 15 Jul 2026.